The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that has been brought forward from other transplant indications. Widely employed on the basis of few small randomized studies, and mostly single-center experience or empirical expert knowledge, anti-rejection therapeutic strategies in pulmonary transplantation have hardly been rigorously evaluated in large-scale prospective international trials. This review compiles the available findings on the use of current immunosuppressants in clinical lung transplantation, accentuating high level-of-evidence study results. Reporting on recent meeting and registry data, and assembling ongoing relevant trials from international databases, this article serves a...
Lung transplantation can improve quality of life and prolong survival for individuals with end-stage...
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. Howev...
Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and...
The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that ...
As a result of advances in surgical techniques, immunosuppressive therapy, and postoperative managem...
Lung transplantation has become a life-saving procedure for individuals with variety of end-stage re...
Lung transplantation offers a realistic treatment option for improved survival and quality of life f...
Lung transplantation is a definitive treatment option for select end-stage lung disease patients. Po...
Objectives: Acute and chronic rejection remain unresolved problems after lung transplantation, despi...
Lung transplantation has become a viable treatment therapy for end-stage lung disease patients. The ...
Lung transplantation has evolved as an accepted therapy in selected adults and children with end-sta...
With an improved median survival of 6.2 years, lung transplantation has become an increasingly accep...
Lung transplantation nowadays is a well-accepted and routine treatment for well selected patients wi...
BACKGROUND Long-term success of lung transplantation is limited by the development of chronic lung a...
ObjectivesAcute and chronic rejection remain unresolved problems after lung transplantation, despite...
Lung transplantation can improve quality of life and prolong survival for individuals with end-stage...
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. Howev...
Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and...
The coming of age of lung transplantation is accompanied by an immunosuppressive armamentarium that ...
As a result of advances in surgical techniques, immunosuppressive therapy, and postoperative managem...
Lung transplantation has become a life-saving procedure for individuals with variety of end-stage re...
Lung transplantation offers a realistic treatment option for improved survival and quality of life f...
Lung transplantation is a definitive treatment option for select end-stage lung disease patients. Po...
Objectives: Acute and chronic rejection remain unresolved problems after lung transplantation, despi...
Lung transplantation has become a viable treatment therapy for end-stage lung disease patients. The ...
Lung transplantation has evolved as an accepted therapy in selected adults and children with end-sta...
With an improved median survival of 6.2 years, lung transplantation has become an increasingly accep...
Lung transplantation nowadays is a well-accepted and routine treatment for well selected patients wi...
BACKGROUND Long-term success of lung transplantation is limited by the development of chronic lung a...
ObjectivesAcute and chronic rejection remain unresolved problems after lung transplantation, despite...
Lung transplantation can improve quality of life and prolong survival for individuals with end-stage...
Lung transplantation is the only definitive therapy for many forms of end-stage lung diseases. Howev...
Induction therapy in lung transplantation: initial single-center experience comparing daclizumab and...